oru.sePublikationer
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Blockers of Angiotensin Other Than Olmesartan in Patients With Villous Atrophy: A Nationwide Case-Control Study
Norwegian Inst Publ Hlth, Div Epidemiol, N-0403 Oslo, Norway.;Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden..
Columbia Univ, Dept Med, Columbia Univ Med Ctr, Celiac Dis Ctr, New York, NY USA..
Columbia Univ, Dept Med, Columbia Univ Med Ctr, Celiac Dis Ctr, New York, NY USA..
Mayo Clin, Dept Med, Div Gastroenterol & Hepatol, Rochester, MN USA.;Mayo Clin, Dept Immunol, Rochester, MN USA..
Show others and affiliations
2015 (English)In: Mayo Clinic proceedings, ISSN 0025-6196, E-ISSN 1942-5546, Vol. 90, no 6, 730-737 p.Article in journal (Refereed) Published
Abstract [en]

Objective: To examine the association between the previous use of nonolmesartan angiotensin receptor blockers (ARBs) or any angiotensin-converting enzyme inhibitor (ACEI) and subsequent villous atrophy (VA) in patients with small-intestinal VA as compared with general population-matched controls. Patients and Methods: A case-control study was used to link nationwide histopathology data on 2933 individuals with VA (Marsh grade 3) to the Swedish Prescribed Drug Register to examine the association between the use of ACEIs as well as the specific use of ARBs other than olmesartan and subsequent VA. Olmesartan is not available in Sweden, so this exposure was not examined. All individuals with VA had biopsies performed between July 1, 2005, and January 29, 2008, and matched on age, sex, calendar period of birth, and county of residence to 14,571 controls from the general population. Results: Use of nonolmesartan ARBs was not associated with VA (odds ratio, 0.84; 95% CI, 0.64-1.09; P = .19). Neither was VA associated with a previous medication of any ACEI (odds ratio, 1.08; 95% CI, 0.90-1.30; P = .41). Restricting the analysis to individuals with repeated prescriptions for ACEIs or ARBs revealed only marginally changed risk estimates for VA. Conclusion: The lack of association between the use of ACEIs and nonolmesartan ARBs and subsequent VA suggests that these medications are not a major risk factor for the development of VA in the general population. (C) 2015 Mayo Foundation for Medical Education and Research

Place, publisher, year, edition, pages
2015. Vol. 90, no 6, 730-737 p.
National Category
Gastroenterology and Hepatology
Identifiers
URN: urn:nbn:se:oru:diva-56535DOI: 10.1016/j.mayocp.2015.04.002ISI: 000355557900009PubMedID: 26046408OAI: oai:DiVA.org:oru-56535DiVA: diva2:1082671
Available from: 2017-03-17 Created: 2017-03-17 Last updated: 2017-03-17Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Ludvigsson, Jonas F.
By organisation
Orebro University Hospital
In the same journal
Mayo Clinic proceedings
Gastroenterology and Hepatology

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 4 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf